Post-marketing surveillance of upadacitinib: multilevel analysis of venous thromboembolism reporting in global data and rheumatoid arthritis.

Of these, 41.3% were VTE, with a slight trend toward an increased risk, particularly in patients with pre-existing cardiovascular risk factors, such as hypertension and a history of smoking.

also in 4,078 other papers

The only exception was among patients aged 18–44 years, for whom the reporting of upadacitinib-associated VTE did not reach statistical significance (IC: 0.27 [–0.02, 0.54]; ROR: 1.32 [1.04, 1.68]) ( Figure 3B ).

also in 111,027 other papers